AT1 mutations and risk of atrial fibrillation based on genotypes from 71000 individuals from the general population

British Journal of Clinical Pharmacology

Volumn 76, Issue 1, 2013, Pages 114-124

  Marott, Sarah C W ^a,b   Nordestgaard, Børge G ^a,b,c   Jensen, Gorm B ^b,c,d   Tybjærg Hansen, Anne ^b,c,e   Benn, Marianne ^a,b  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b Mental Health Center Glostrup   (Denmark)

^c BISPEBJERG HOSPITAL   (Denmark)

^d HVIDOVRE HOSPITAL   (Denmark)

^e University of Copenhagen   (Denmark)

Author keywords

AT1 gene; Atrial fibrillation; Epidemiology; Genetics

Indexed keywords

ANGIOTENSIN 1 RECEPTOR;

ADULT; AGED; ARTICLE; CORRELATION ANALYSIS; DISEASE PREDISPOSITION; FEMALE; GENE MUTATION; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART INFARCTION; HETEROZYGOSITY; HETEROZYGOTE; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN FUNCTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK FACTOR; DENMARK; GENETIC PREDISPOSITION; GENETICS; MIDDLE AGED; MUTATION; PROSPECTIVE STUDY; RISK; SEX DIFFERENCE;

AGED; ATRIAL FIBRILLATION; DENMARK; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; GENOTYPE; HETEROZYGOTE; HUMANS; MALE; MIDDLE AGED; MUTATION; PROSPECTIVE STUDIES; RECEPTOR, ANGIOTENSIN, TYPE 1; RISK; SEX FACTORS;

EID: 84879491582     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12050     Document Type: Article

References (32)

1. Alexander SP, Mathie A, Peters JA. Guide to Receptors and Channels (GRAC), 5th edition. Br J Pharmacol 2011; 164: (Suppl. 1): S1-324.
2. Hunyady L, Catt KJ. Pleiotropic AT1 receptor signaling pathways mediating physiological and pathogenic actions of angiotensin II. Mol Endocrinol 2006; 20: 953-970.
3. Lau YF, Yiu KH, Siu CW, Tse HF. Hypertension and atrial fibrillation: epidemiology, pathophysiology and therapeutic implications. J Hum Hypertens 2011; 26: 563-569.
4. Tsai CT, Lai LP, Lin JL, Chiang FT, Hwang JJ, Ritchie MD, Moore JH, Hsu KL, Tseng CD, Liau CS, Tseng YZ. Renin-angiotensin system gene polymorphisms and atrial fibrillation. Circulation 2004; 109: 1640-1646.
5. Schneider MP, Hua TA, Bohm M, Wachtell K, Kjeldsen SE, Schmieder RE. Prevention of atrial fibrillation by Renin-Angiotensin system inhibition a meta-analysis. J Am Coll Cardiol 2010; 55: 2299-2307.
6. Goette A. The vanishing story of angiotensin II receptor blockers in the treatment of atrial fibrillation. Europace 2011; 13: 451-452.
7. Nordestgaard BG, Benn M, Schnohr P, Tybjaerg-Hansen A. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA 2007; 298: 299-308.
8. Fuster V, Ryden LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, Halperin JL, Kay GN, Le Huezey JY, Lowe JE, Olsson SB, Prystowsky EN, Tamargo JL, Wann LS. 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 Guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in partnership with the European Society of Cardiology and in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. J Am Coll Cardiol 2011; 57: e101-e198.
9. Friberg J, Scharling H, Gadsboll N, Jensen GB. Sex-specific increase in the prevalence of atrial fibrillation (The Copenhagen City Heart Study). Am J Cardiol 2003; 92: 1419-1423.
10. Jespersen CG, Borre M, Norgaard M. Validity of the recorded codes of gonadotropin-releasing hormone agonist treatment and orchiectomies in the Danish National Patient Registry. Clin Epidemiol 2012; 4: 145-149.
11. Juel K, Helweg-Larsen K. The Danish registers of causes of death. Dan Med Bull 1999; 46: 354-357.
12. Finucane TE. NICE guideline for management of chronic heart failure in adults. Ann Intern Med 2012; 156: 69-70.
13. Thygesen K, Alpert JS, White HD. Universal definition of myocardial infarction. J Am Coll Cardiol 2007; 50: 2173-2195.
14. Ng PC, Henikoff S. SIFT: predicting amino acid changes that affect protein function. Nucleic Acids Res 2003; 31: 3812-3814.
15. Thomas PD, Kejariwal A, Campbell MJ, Mi H, Diemer K, Guo N, Ladunga I, Ulitsky-Lazareva B, Muruganujan A, Rabkin S, Vandergriff JA, Doremieux O. PANTHER: a browsable database of gene products organized by biological function, using curated protein family and subfamily classification. Nucleic Acids Res 2003; 31: 334-341.
16. Ehrlich JR, Hohnloser SH, Nattel S. Role of angiotensin system and effects of its inhibition in atrial fibrillation: clinical and experimental evidence. Eur Heart J 2006; 27: 512-518.
17. Goette A, Staack T, Rocken C, Arndt M, Geller JC, Huth C, Ansorge S, Klein HU, Lendeckel U. Increased expression of extracellular signal-regulated kinase and angiotensin-converting enzyme in human atria during atrial fibrillation. J Am Coll Cardiol 2000; 35: 1669-1677.
18. Goette A, Arndt M, Rocken C, Spiess A, Staack T, Geller JC, Huth C, Ansorge S, Klein HU, Lendeckel U. Regulation of angiotensin II receptor subtypes during atrial fibrillation in humans. Circulation 2000; 101: 2678-2681.
19. Roberts R. Mechanisms of disease: genetic mechanisms of atrial fibrillation. Nat Clin Pract Cardiovasc Med 2006; 3: 276-282.
20. Ravn LS, Benn M, Nordestgaard BG, Sethi AA, Agerholm-Larsen B, Jensen GB, Tybjaerg-Hansen A. Angiotensinogen and ACE gene polymorphisms and risk of atrial fibrillation in the general population. Pharmacogenet Genomics 2008; 18: 525-533.
21. Topal NP, Ozben B, Hancer VS, Tanrikulu AM, Diz-Kucukkaya R, Fak AS, Basaran Y, Yesildag O. Polymorphisms of the angiotensin-converting enzyme and angiotensinogen gene in patients with atrial fibrillation. J Renin Angiotensin Aldosterone Syst 2011; 12: 549-556.
22. Wang QS, Li YG, Chen XD, Yu JF, Wang J, Sun J, Lu SB, Jin L, Wang XF. Angiotensinogen polymorphisms and acquired atrial fibrillation in Chinese. J Electrocardiol 2010; 43: 373-377.
23. Liu T, Korantzopoulos P, Xu G, Shehata M, Li D, Wang X, Li G. Association between angiotensin-converting enzyme insertion/deletion gene polymorphism and atrial fibrillation: a meta-analysis. Europace 2011; 13: 346-354.
24. Belenkov YN, Privalova EV, Kaplunova VY, Stambol'skii DV, Fomin AA. [Analysis of morpho-functional parameters of the heart and polymorphisms of Renin-Angiotensin-aldosterone system genes in patients with different variants of the course of hypertrophic cardiomyopathy]. Kardiologiia 2010; 50: 27-34.
25. Aplin M, Bonde MM, Hansen JL. Molecular determinants of angiotensin II type 1 receptor functional selectivity. J Mol Cell Cardiol 2009; 46: 15-24.
26. Kobilka BK. G protein coupled receptor structure and activation. Biochim Biophys Acta 2007; 1768: 794-807.
27. Ballesteros JA, Shi L, Javitch JA. Structural mimicry in G protein-coupled receptors: implications of the high-resolution structure of rhodopsin for structure-function analysis of rhodopsin-like receptors. Mol Pharmacol 2001; 60: 1-19.
28. Farrens DL, Altenbach C, Yang K, Hubbell WL, Khorana HG. Requirement of rigid-body motion of transmembrane helices for light activation of rhodopsin. Science 1996; 274: 768-770.
29. Gether U, Lin S, Ghanouni P, Ballesteros JA, Weinstein H, Kobilka BK. Agonists induce conformational changes in transmembrane domains III and VI of the beta2 adrenoceptor. EMBO J 1997; 16: 6737-6747.
30. Sheikh SP, Zvyaga TA, Lichtarge O, Sakmar TP, Bourne HR. Rhodopsin activation blocked by metal-ion-binding sites linking transmembrane helices C and F. Nature 1996; 383: 347-350.
31. Parnot C, Miserey-Lenkei S, Bardin S, Corvol P, Clauser E. Lessons from constitutively active mutants of G protein-coupled receptors. Trends Endocrinol Metab 2002; 13: 336-343.
32. Parnot C, Bardin S, Miserey-Lenkei S, Guedin D, Corvol P, Clauser E. Systematic identification of mutations that constitutively activate the angiotensin II type 1A receptor by screening a randomly mutated cDNA library with an original pharmacological bioassay. Proc Natl Acad Sci U S A 2000; 97: 7615-7620.